Clinical trials in amyotrophic lateral sclerosis

Area of Science:

• Neurology
• Clinical Trials
• Drug Development

Background:

• Amyotrophic lateral sclerosis (ALS) research has faced decades of clinical trial disappointments.
• A deeper understanding of ALS biology is crucial for therapeutic advancements.

Purpose of the Study:

• To review recent advancements in amyotrophic lateral sclerosis (ALS) clinical trial design.
• To analyze the implications of the latest ALS clinical trials for future research and patient care.

Main Methods:

• Review of revised Airlie House recommendations for ALS trial design.
• Analysis of innovative approaches including individualized eligibility criteria, adaptive designs, and remote data collection.
• Evaluation of recent clinical trial outcomes for drugs like edaravone, arimoclomol, inosine, and rasagaline.

Main Results:

• Edaravone demonstrated functional benefits in a specific ALS patient subset.
• Early-phase studies of arimoclomol, inosine, and cellular therapies show promising signals.
• Rasagaline studies did not yield positive results on primary outcome measures.

Conclusions:

• Innovations in clinical trial design, such as adaptive methods and patient-centered approaches, are improving the prospects for ALS treatment development.
• Despite past disappointments, current advancements in trial design and basic science offer strong potential for a treatment breakthrough in ALS.